Get the Stockscreener App
4.52
1.32%
0.010
Tvardi Therapeutics Inc stock is traded at $4.52, with a volume of 55,830.
It is up +1.32% in the last 24 hours and down -88.64% over the past month.
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.
See More
Previous Close:
$4.51
Open:
$4.44
24h Volume:
55,830
Relative Volume:
0.23
Market Cap:
$42.39M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-3.19%
1M Performance:
-88.64%
6M Performance:
-82.90%
1Y Performance:
+0.00%
1-Day Range:
$4.40
$4.5699
1-Week Range:
$4.40
$5.00
52-Week Range:
$4.40
$43.65
Tvardi Therapeutics Inc Stock (TVRD) Company Profile
Name
Tvardi Therapeutics Inc
Sector
Industry
Phone
(713) 489-8654
Address
3 SUGAR CREEK CTR. BLVD., SUGAR LAND
Compare TVRD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TVRD
Tvardi Therapeutics Inc
|
4.52 | 42.29M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
429.74 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
635.54 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
426.69 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
842.34 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
185.21 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Tvardi Therapeutics Inc Stock (TVRD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-14-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Oct-14-25 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Oct-13-25 | Initiated | Barclays | Overweight |
| Oct-13-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Oct-13-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-14-25 | Initiated | Raymond James | Outperform |
| Jul-11-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-12-25 | Initiated | Piper Sandler | Overweight |
| May-21-25 | Initiated | Oppenheimer | Outperform |
| May-15-25 | Initiated | BTIG Research | Buy |
| Jun-13-24 | Downgrade | Canaccord Genuity | Buy → Hold |
| Jun-13-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jun-13-24 | Downgrade | Needham | Buy → Hold |
| Jun-13-24 | Downgrade | Stifel | Buy → Hold |
| Mar-08-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Mar-08-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Nov-01-21 | Resumed | Canaccord Genuity | Buy |
| Aug-03-21 | Initiated | JP Morgan | Neutral |
| Apr-21-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-12-19 | Reiterated | H.C. Wainwright | Buy |
| May-29-19 | Reiterated | Laidlaw | Buy |
| Feb-06-19 | Resumed | Jefferies | Buy |
| Jan-15-19 | Initiated | BofA/Merrill | Neutral |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-13-18 | Initiated | Jefferies | Buy |
| Aug-08-18 | Reiterated | Stifel | Buy |
| Jun-28-18 | Reiterated | H.C. Wainwright | Buy |
| Mar-12-18 | Resumed | H.C. Wainwright | Buy |
| Feb-12-18 | Upgrade | Janney | Neutral → Buy |
| Jan-19-18 | Initiated | Seaport Global Securities | Buy |
View All
Tvardi Therapeutics Inc Stock (TVRD) Latest News
Tvardi Therapeutics to Participate in the Jefferies Global Healthcare Conference in London - MarketScreener
Is Tvardi Therapeutics Inc. stock ready for a breakoutWeekly Trend Summary & AI Based Trade Execution Alerts - newser.com
Is Tvardi Therapeutics Inc. (69C) stock a safe buy pre earnings2025 Technical Patterns & High Yield Stock Recommendations - newser.com
How to track smart money flows in Tvardi Therapeutics Inc.July 2025 Momentum & Accurate Entry and Exit Point Alerts - newser.com
Technical signs of recovery in Tvardi Therapeutics Inc.2025 Major Catalysts & Technical Entry and Exit Tips - newser.com
Tvardi Therapeutics (TVRD) Competitors and Alternatives 2025 - MarketBeat
Shareholders Alert: Investigation Into Tvardi Therapeutics, Inc. (TVRD)Contact Levi & Korsinsky to Protect Your Rights - ACCESS Newswire
Tvardi Therapeutics, Inc. (TVRD) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics - The Malaysian Reserve
Why Tvardi Therapeutics Inc. (69C) stock could outperform next yearWeekly Volume Report & High Yield Equity Trading Tips - newser.com
Measuring Tvardi Therapeutics Inc.’s beta against major indicesWeekly Investment Report & Weekly Watchlist of Top Performers - newser.com
Understanding Tvardi Therapeutics Inc.’s price movementIPO Watch & Reliable Entry Point Alerts - newser.com
Does Tvardi Therapeutics Inc. stock trade at a discount to peersChart Signals & Reliable Price Action Trade Plans - newser.com
Can Tvardi Therapeutics Inc. (69C) stock hold up in economic slowdownMarket Performance Report & Daily Price Action Insights - newser.com
Will Tvardi Therapeutics Inc. stock benefit from green energy trendsWeekly Investment Recap & Weekly Return Optimization Plans - newser.com
What data driven models say about Tvardi Therapeutics Inc.’s futureJuly 2025 Final Week & Technical Pattern Recognition Alerts - newser.com
Heatmap analysis for Tvardi Therapeutics Inc. and competitors2025 Big Picture & Real-Time Volume Surge Alerts - newser.com
How to interpret RSI for Tvardi Therapeutics Inc. stockTake Profit & Weekly Breakout Stock Alerts - newser.com
Can Tvardi Therapeutics Inc. stock deliver consistent earnings growthJuly 2025 Movers & AI Based Buy and Sell Signals - newser.com
Using Bollinger Bands to evaluate Tvardi Therapeutics Inc.July 2025 Intraday Action & Free Fast Gain Swing Trade Alerts - newser.com
Key resistance and support levels for Tvardi Therapeutics Inc.Portfolio Growth Summary & High Accuracy Buy Signal Tips - newser.com
What to do if you’re stuck in Tvardi Therapeutics Inc.July 2025 Pullbacks & Safe Capital Growth Stock Tips - newser.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Tvardi Therapeutics, Inc. (TVRD) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
2025-11-02 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Tvardi Therapeutics, Inc. (TVRD) and Encourages Investors to Learn More About the Investigation | NDAQ:TVRD | Press Release - Stockhouse
Tvardi Therapeutics, Inc. (TVRD) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
Why Tvardi Therapeutics Inc. stock is recommended by analystsJuly 2025 Highlights & Free Low Drawdown Momentum Trade Ideas - newser.com
How Tvardi Therapeutics Inc. stock reacts to global recession fears2025 Support & Resistance & Verified Swing Trading Watchlists - newser.com
Will Tvardi Therapeutics Inc. benefit from macro trendsJuly 2025 Review & Capital Protection Trading Alerts - newser.com
TVRD Investors Have Opportunity to Join Tvardi Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - The AI Journal
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Tvardi Therapeutics, Inc. (TVRD) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
2025-10-31 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Tvardi Therapeutics, Inc. (TVRD) and Encourages Stockholders to Learn More About the Investigation | NDAQ:TVRD | Press Release - Stockhouse
Using AI based signals to follow Tvardi Therapeutics Inc.2025 Market Sentiment & Breakout Confirmation Trade Signals - newser.com
Tvardi Therapeutics Inc Stock (TVRD) Financials Data
There is no financial data for Tvardi Therapeutics Inc (TVRD). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.85%
0.26%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):